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Abstract
Background: Obstructive sleep apnea (OSA) is characterized by repeated episodes of obstruction of the upper
airway. Numerous studies have indicated a relationship between OSA and metabolic syndrome (MS), but the results
remain debatable. We aimed to perform a systematic review and meta-analysis to evaluate the association between
OSA and MS.
Methods: We searched electronic databases (PubMed, EMBASE, and ISO Web of Knowledge) up to September
2014 with English-language restriction. Cross-sectional, case–control, and cohort studies in which the presence of
OSA was assessed by objective measurements, the exposure of interest was OSA, and the outcome of interest
was the presence (or incidence) of MS were included. The adjusted odds ratios (ORs) (or relative risk) and 95 %
confidence intervals (CIs) were extracted and pooled. Sensitivity analyses were conducted, and heterogeneity and
publication bias were assessed.
Results: Overall, 15 cross-sectional (2456 patients with OSA and 1705 subjects without OSA), five case–control
(1156 OSA patients and 404 controls), and no cohort studies were included. The pooled ORs of MS in individuals
with OSA for cross-sectional and case–control studies were 2.87 (95 % CI: 2.41–3.42) and 2.56 (95 % CI: 1.98–3.31),
respectively. There was clinically unimportant (I2 = 20 %) and moderate (I2 = 35 %) between-study heterogeneity of
the analysis. The pooled crude ORs of MS in individuals with mild and moderate-to-severe OSA was 2.39 (95 % CI:
1.65–3.46) and 3.45 (95 % CI: 2.33–5.12), respectively, and there was substantial heterogeneity in the meta-analyses
(I2 = 53 % and I2 = 63 %, respectively). However, no evidence of publication bias was detected.
Conclusions: OSA is shown to be associated with MS, although causality between these two factors has not been
demonstrated yet. Future cohort and randomized controlled studies are needed.
Keywords: Obstructive sleep apnea, Metabolic syndrome, Meta-analysis, Cross-sectional study, Case–control study,
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Background
Obstructive sleep apnea (OSA) is a condition in which
there is repetitive obstruction of the upper airway during
sleep, resulting in hypopnea (reduced airflow during sleep)
or apnea (complete cessation of airflow during sleep)
[1, 2]. Patients with OSA may experience symptoms,
including loud souring, frequent arousals, sleep frag-
mentation, and daytime sleepiness, which characterize
obstructive sleep apnea syndrome [2, 3]. Studies have
shown that OSA is associated with increased risks of
hypertension, stroke, type 2 diabetes mellitus, and other
cardiovascular diseases [4–7]. Approximately 4 % of men
and 2 % of women in the general population were consid-
ered as having OSA in 1993 [8, 9]. With the increasing
epidemic of obesity, the prevalence of OSA among adults
is estimated to be up to 17 % [10].
Metabolic syndrome (MS) is a cluster of metabolic risk
factors for diabetes and cardiovascular diseases, including
central obesity, hypertension, hyperglycemia, and dyslipid-
emia [11–13]. The prevalence of MS varies between 20
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and 40 % worldwide and tends to increase in parallel with
the epidemic of obesity [14, 15]. In the past decade, nu-
merous studies have indicated a relationship between
OSA and MS, but the results remain debatable [16].
Coughlin et al. found that OSA was independently associ-
ated with an increased risk of MS, irrespective of age and
body mass index (BMI) [17]. However, Papanas et al.
showed that the strong association between the presence
of OSA and MS became non-significant when BMI was
considered [18].
Based on these findings, and the fact that no meta-
analysis has been conducted on this relationship, we
aimed to perform a systematic review and meta-analysis
to evaluate the association between OSA and MS.
Methods
Search strategy
We followed the guidelines of the Meta-analysis of
Observational Studies in Epidemiology group in reporting
the meta-analysis [19]. We searched electronic databases
(PubMed, EMBASE, and ISO Web of Knowledge) up to
September 2014 using the following terms: “obstructive
sleep apnea (apnoea)” or “sleep apnea (apnoea) syndrome”
or “sleep-disordered breathing” or “OSA” or “SAS” or
“SDB” and “metabolic syndrome” or “insulin resistance
syndrome” or “metabolic syndrome X” or “syndrome X”
(Additional file 1). We also checked the reference lists
from the included studies and relevant review articles for
potential publications that might be suitable for inclusion.
English-language restriction was applied.
Two reviewers (S.X. and J.M.) independently checked
titles and abstracts against the eligibility criteria and
obtained full-text versions of potentially relevant articles.
Disagreements were discussed with a third party (Y.W.
and Q.J.) before a final decision on inclusion.
Identification of studies
Cross-sectional, case–control, and cohort studies in
which the presence of OSA was assessed by standard ob-
jective measurements were included. Polysomnography
(PSG), which must be performed in a sleep laboratory
setting, is considered the reference standard for diagnos-
ing OSA [20, 21]. Therefore, studies that used type IV
monitors, which cannot differentiate between obstruct-
ive and central apneas, devices that cannot estimate the
apnea–hypopnea index (AHI), questionnaires, or self-
reported snoring to assess OSA were excluded. Studies
in which the exposure of interest was OSA and the out-
come of interest was the presence (for case–control and
cross-sectional studies) or incidence (for cohort studies)
of MS were included. For studies to be eligible for inclu-
sion, they must have reported (or provided sufficient
data to enable the calculation of ) a risk estimate for MS
related to OSA, together with a 95 % confidence interval
(CI), a P value, or a standard error (SE). Literature re-
views, letters, and comments were excluded. Conference
reports that were not subsequently published were ex-
cluded in the main body, but included as sensitivity ana-
lyses, which are available online as Additional files.
Data collection
Two reviewers (S.X. and J.M.) independently extracted
data from all eligible studies by using a standardized ex-
traction form (agreement was 98.5 %). The third party
(Y.W. and Q.J) checked the data and resolved the dis-
crepancies by discussing and cross-checking against the
primary papers.
The data included the following: first author’s name,
publication year, study type, location of study, enroll-
ment criteria of patients, method and criteria of defining
OSA and MS, sample size, mean age of the patients, per-
centage of male sex, mean BMI, history of smoking and
drinking, number and percentage of patients in both
groups, crude and adjusted odds ratios (ORs) (for
case–control and cross-sectional studies) or relative
risks (RRs) (for cohort studies), and adjusted confounders
(if provided). The data were recorded in a preformatted
Excel spreadsheet.
Assessment of methodological quality
The methodological quality of the included studies was
evaluated based on the Newcastle–Ottawa Scale (NOS)
[22], by appraising the following characteristics (an ex-
ample for case–control and cross-sectional studies):
1. Selection (4 items): adequacy of case definition;
representativeness of the cases; selection of controls;
and definition of controls.
2. Comparability (1 item): comparability of cases and
controls on the basis of the design or analysis.
3. Exposure (3 items): ascertainment of exposure; same
method of ascertainment for cases and controls; and
non-response rate (same rate for both groups).
A star rating system was used to indicate the quality of a
study, with a maximum of nine stars. A study could be
awarded a maximum of one star for each numbered item
within the selection and exposure categories. A maximum
of two stars could be allocated for comparability; one star
was allocated if the most important confounder had been
adjusted for in the analysis and a second star was allocated
if any other adjustments were made.
Severity of OSA
The AHI was defined as the mean number of episodes
of apnea and hypopnea per hour of sleep. OSA severity
categories were defined according to commonly used
clinical cutoffs as follows [21]: no OSA (AHI < 5 events/h);
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mild OSA (AHI ≥ 5 events/h but < 15 events/h); moderate
OSA (AHI ≥ 15 events/h but < 30 events/h); and severe
OSA (AHI ≥ 30 events/h). For studies that used an AHI ≥
10 or 15 events/h as diagnosis of OSA, the severity of
OSA was based on the authors’ opinion.
Statistical analysis
All of the statistical analyses were conducted by using
RevMan 5.1 software (The Nordic Cochrane Centre, The
Cochrane Collaboration, 2011) or Stata 10.0 (StataCorp,
College Station, TX, USA). The association between
OSA and MS was assessed based on cross-sectional,
case–control, and cohort studies, separately. The pooled
ORs for cross-sectional and case–control studies, and
RRs for cohort studies, were generated separately. The
adjusted ORs (or RRs) (obesity was considered the most
important factor) were preferred for the meta-analysis,
and calculation of crude ORs based on the raw data
was also adopted in case of the absence of adjusted ORs
(or RRs). Subgroup meta-analyses were performed be-
cause of the multiple criteria of OSA (i.e., AHI ≥ 5 events/
h, ≥ 10 events/h, or ≥ 15 events/h). Where results were
separately reported for men and women or for mild and
moderate-to-severe OSA, they were initially pooled within
the study, and then a single estimate was included in
the meta-analysis. In addition, a random effects model
(if substantial heterogeneity was present) or a fixed
effects model (if substantial heterogeneity was not
present) was used to assess study heterogeneity by using
the Cochrane Q-test, the I2 test, and the Galbraith
plot (if necessary) [23]. Heterogeneity was considered to
be significant at P < 0.10 for the Q statistic. We defined I2
values below 30 % as unimportant, 30–50 % as moderate
heterogeneity, 51–75 % as substantial heterogeneity, and
>75 % as considerable heterogeneity. Meta-regression ana-
lyses were performed to evaluate the effect of mean BMI,
mean patient’s age, percentage of male sex, adjusted
status (yes/no), and publication year.
Subgroup analyses were conducted to test the ro-
bustness of the findings (e.g., based on the exclusion
of studies that provided unadjusted data only, or on
the exclusion of studies that used different parameters
in the selection of participants or MS definitions).
Furthermore, the Begg’s test [24] and Egger’s test [25]
were used to evaluate publication bias, which was further
assessed by using funnel plots.
Results
Overall, 5648 references were identified and 20 studies
were finally included in the review [17, 18, 26–43]. All of
the included studies were reviewed by full text. Of the in-
cluded studies, 15 were cross-sectional [18, 26–33, 35–37,
40, 42, 43], five were case–control [17, 34, 38, 39, 41], and
none were cohort studies. In total, 2456 patients with
OSA and 1705 subjects with no OSA in cross-sectional
studies, together with 1156 OSA patients and 404 controls
in case–control studies, were included in the meta-
analysis for the association of OSA with MS (Fig. 1).
Fourteen studies were hospital-based studies [17, 18,
28–34, 37–41], five were community-based studies [26,
35, 36, 42, 43], and one was a population-based study [27].
All of the studies used the AHI based on an overnight
PSG to diagnose OSA, whereas the AHI thresholds dif-
fered between studies. Two studies [44, 45], of which one
used the minimal patient contact sleep diagnosis system
and another used a pulse-oximeter to assess OSA, were
excluded. Almost all of the studies adopted the National
Cholesterol Education Program Adult Treatment Panel III
criteria to define MS, except for one study [39] in which
the International Diabetes Federation criteria were used
(Table 1).
The NOS [22] was used to evaluate the methodo-
logical quality of the included studies (Table 2). The
mean NOS score for the cross-sectional and case–con-
trol studies was 6.7 and 6.8, respectively, indicating that
the overall methodological quality was generally good.
Fourteen hospital-based studies had relatively low scores
in the selection category, mainly because the controls
who were derived from a hospitalized population (not
the same community) may have resulted in potential se-
lection bias. In the comparability category, obesity was
the most important factor, but was adjusted for in only
seven studies [17, 26, 32, 34, 35, 39, 43]. In the exposure
category, all of the studies had perfect scores for the
ideal and same method of ascertainment for cases and
controls. Venous blood was obtained to assess MS in the
fasting state in the morning after performing PSG in al-
most all of the prospective studies. Therefore, we were
cautious that they had nearly a 100 % response rate for
both groups. Two studies did not receive stars in the item
of non-response rate [26, 28]. One of these studies was a
retrospective study in which the authors mentioned that
22 patients were excluded for insufficient data, but they
did not report the non-response rate in each group separ-
ately [28]. The other study was a community-based study
in which a subset of participants from the Wisconsin
Sleep Cohort Study were invited to measure metabolic pa-
rameters; therefore, the non-response rate for each group
should have been described [26].
As mentioned above, the adjusted ORs were preferred
for the meta-analysis. For the remaining studies without
adjusted ORs, the crude or calculated ORs were adopted
for the meta-analysis. Sensitivity analysis was then per-
formed based on the exclusion of studies that provided
unadjusted data only. Two studies separately reported
the adjusted ORs for men and women [39] or for mild
and moderate-to-severe OSA [26]. The results were ini-
tially pooled within the study and then a single estimate
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was included in the meta-analysis. Overall, for cross-
sectional studies, the pooled OR of MS in individuals
with OSA was 2.87 (95 % CI: 2.41–3.42), with unimport-
ant between-study heterogeneity of the analysis (P =
0.23, I2 = 20 %). Subgroup meta-analyses based on the
criteria of OSA (AHI > 5 events/h or > 15 events/h)
showed similar pooled ORs (2.89 [95 % CI: 2.39–3.50]
and 2.73 [95 % CI: 1.74–4.28], respectively). There was
no evidence of substantial heterogeneity in the subgroup
analyses (P = 0.13, I2 = 31 % and P = 0.91, I2 = 0 %, re-
spectively) (Fig. 2). For case–control studies, the pooled
OR of MS in individuals with OSA was 2.56 (95 % CI:
1.98–3.31), with moderate between-study heterogeneity
of the analysis (P = 0.19, I2 = 35 %). Subgroup meta-
analyses based on the criteria of OSA (AHI > 5 events/h
or > 10 events/h [15 events/h]) showed similar pooled
ORs (2.11 [95 % CI: 1.50–2.96] and 3.29 [95 % CI: 2.23–
4.85], respectively). The I2 was 0 % (P = 0.96) and 39 %
(P = 0.19), respectively (Fig. 3). In addition, mixed effect,
multilevel meta-analyses showed no effects of mean
BMI, mean patient’s age, percentage of male sex, ad-
justed (yes/no), and publication year on the overall re-
sults (P > 0.05 for all analyses).
Only some of the cross-sectional studies and one
case–control study provided data on severity of OSA re-
lated to MS. Therefore, meta-analysis on the relationship
between MS and the severity of OSA was conducted in
all of the eligible studies together. The pooled crude
ORs of MS in individuals with mild and moderate-to-
severe OSA were 2.39 (95 % CI: 1.65–3.46) and 3.45
(95 % CI: 2.33–5.12), respectively. There was substantial
heterogeneity in the meta-analyses (P = 0.02, I2 = 53 %
and P = 0.004, I2 = 63 %, respectively) (Fig. 4).
To verify the robustness of the results, as well as the po-
tential sources of heterogeneity, subgroup analyses were
performed. We examined exclusion of studies with obesity
as the most important unadjusted factor (Model 1), those
where the Adult Treatment Panel III criteria were not
used to define MS (Model 2), and those with a special
population (children, young men, morbidly obese individ-
uals, and non-obese people) (Model 3). These subgroup
analyses only resulted in a marginal change in the pooled
ORs (Table 3).
No evidence of publication bias was detected by using
Begg’s test (z = 1.18, P = 0.232) and Egger’s test (z = 1.18,
P = 0.232). Visual inspection of the funnel plots showed
that they were symmetrical (Fig. 5).
We also performed meta-analyses that included
two conference reports that were not subsequently
published [46, 47]. The results were similar to those
that did not include conference reports, although there
was substantial heterogeneity in the meta-analyses.
Fig. 1 Flow chart of the process of article selection for meta-analysis. OSA: obstructive sleep apnea; MS: metabolic syndrome; CVD:
cardiovascular disease
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Table 1 Characteristics of the included studies on obstructive sleep apnea and the risk of metabolic syndrome








N % MS N % MS Adjusted OR (95 % CI) Confounder
Cross-sectional study
Jamie C.M. Lam, 2006 [35] Community-based study,
Hong Kong, China




James M. Parish, 2007 [28] Retrospective hospital-based
study, United states
PSG; AHI≥ 5 events/h
or ≥10 events/h
ATP III 174 56 % 54 43 % No 1.74 (0.94–3.22) None 5
Susan Redline, 2007 [43] Two-stage community-based
study, United States
PSG; AHI ≥5 events/h. Adapted
ATP III
22 59 % 248 16 % Yes 6.49 (2.52–16.70) Age, sex, race and
preterm status.
9
F. Javier Nieto, 2009 [26] Community-based study,
United states
PSG; AHI ≥5 events/h. ATP III 253 ——— 293 ——— Yes 2.37 (1.60–3.50) Age, sex, BMI 8
Francesco Angelico, 2010 [31] Hospital-based study, Italy PSG; AHI >5 events/h. ATP III 178 53.9 % 48 42.6 % No 1.64 (0.86–3.12) None 6
Stephen Guill, 2010 [42] Community and web-based
study, United States
PSG. AHI >5 events/h. ATP III 12 33 % 18 28 % No 1.30 (0.27–6.33) None 6
Nikolaos Papanas, 2010 [18] Hospital-based study, Greece PSG; AHI >5 events/h ATP III 53 71.7 % 30 36.7 % No 4.38 (1.69–11.35) None 6
Swastik Agrawal, 2011 [30] Hospital-based study,
Northern India
PSG; AHI >5 events/h. ATP III 187 79 % 40 48 % No 4.19 (2.05–8.56) None 6
H.-W.M. Breuer, 2011 [40] Hospital-based study,
Germany.
PSG; AHI≥ 5 events/h. ATP III or
IDF
360 47 % 58 26 % No 2.54 (1.36–4.73) None 6
M. Gasa, 2011 [32] Multi hospital-based study,
Spain
PSG; AHI≥ 15 events/h. ATP III 114 70 % 44 36 % Yes 2.84 (1.30–6.22) Age, gender and BMI 8
Duygu Ozol, 2011 [29] Hospital-based study, Ankara,
Turkey
PSG; AHI ≥5 events/h. ATP III 195 23.8 % 20 10.0 % No 2.81 (0.61–12.97) None 6
Jenny Theorell-Haglöw, 2011 [27] Two-stage population-based
study, Sweden
PSG; AHI ≥5 events/h. ATP III 135 44.4 % 265 16.2 % No 4.13 (2.58–6.62) None 7
Assoumou HG, 2012 [36] Community-based study,
France
PSG; AHI >15 events/h ATP III 449 12.5 % 357 5 % No 2.68 (1.55–4.65) None 7
Qi-Chang Lin, 2012 [33] Hospital-based study, China PSG; AHI ≥5 events/h. Modified
ATP III
113 38.9 % 45 8.9 % No 6.54 (2.19–19.52) None 6
Bienvenido Barreiro, 2013 [37] Hospital-based study,
Barcelona, Spain
PSG; AHI ≥5 events/h. ATP III 116 68 % 25 32 % No 4.36 (1.73–11.01) None 5
Case–control study
Steven R. Coughlin, 2004 [17] Hospital-based study, United
kingdom


















Table 1 Characteristics of the included studies on obstructive sleep apnea and the risk of metabolic syndrome (Continued)
Bharat Bhushan, 2010 [34] Hospital-based study,
Northern India
PSG; AHI > 10 events/h. ATP III 121 67.8 % 119 42.0 % Yes 3.40 (1.93–6.05) Age, BMI, smoking, and
alcohol consumption
8
Ozen K. Basoglu, 2011 [38] Hospital-based study, Izmir,
Turkey
PSG; AHI ≥5 events/h ATP III 36 47.2 % 34 29.4 % No 2.15 (0.80–5.76) None 6
A. Barcelo, 2011 [41] Hospital-based study, Spain PSG; AHI ≥10 events/h. ATP III 119 38.0 % 119 21.0 % No 2.54 (1.41–4.56) None 5
OSA obstructive sleep apnea, MS metabolic syndrome, OR odds ratio, CI confidence interval, NOS Newcastle-Ottawa Scale, AHI apnea–hypopnea index, BMI body mass index, ATP Adult Treatment Panel, IDF International














Table 2 Scores of Newcastle-Ottawa quality assessment scale
Studies Selection Comparability Exposure Total
scale1 2 3 4 5A 5B 6 7 8
Cross-sectional study
Jamie C.M. Lam, 2006 [35] Yes Yes Yes Yes Yes Yes Yes Yes Yes 9
James M. Parish, 2007 [28] Yes Yes No Yes No No Yes Yes No 5
Susan Redline, 2007 [43] Yes Yes Yes Yes Yes Yes Yes Yes Yes 9
F. Javier Nieto, 2009 [26] Yes Yes Yes Yes Yes Yes Yes Yes No 8
Francesco Angelico, 2010 [31] Yes Yes No Yes No No Yes Yes Yes 6
Stephen Guill, 2010 [42] Yes No Yes Yes No No Yes Yes Yes 6
Nikolaos Papanas, 2010 [18] Yes Yes No Yes No No Yes Yes Yes 6
Swastik Agrawal, 2011 [30] Yes Yes No Yes No No Yes Yes Yes 6
H.-W.M. Breuer, 2011 [40] Yes Yes No Yes No No Yes Yes Yes 6
M. Gasa, 2011 [32] Yes Yes No Yes Yes Yes Yes Yes Yes 8
Duygu Ozol, 2011 [29] Yes Yes No Yes No No Yes Yes Yes 6
Jenny Theorell-Haglöw, 2011 [27] Yes Yes Yes Yes No No Yes Yes Yes 7
Assoumou HG, 2012 [36] Yes Yes Yes Yes No No Yes Yes Yes 7
Qi-Chang Lin, 2012 [33] Yes Yes No Yes No No Yes Yes Yes 6
Bienvenido Barreiro, 2013 [37] Yes No No Yes No No Yes Yes Yes 5
Case–control study
Steven R. Coughlin, 2004 [17] Yes No No Yes Yes Yes Yes Yes Yes 7
Ryujiro Sasanabe, 2006 [39] Yes Yes No Yes Yes Yes Yes Yes Yes 8
Bharat Bhushan, 2010 [34] Yes No No Yes Yes Yes Yes Yes Yes 8
Ozen K. Basoglu, 2011 [38] Yes Yes No Yes No No Yes Yes Yes 6
A. Barcelo, 2011 [41] Yes No No Yes No No Yes Yes Yes 5
A star rating system was used to indicate the quality of a study, with a maximum of nine stars. A study could be awarded a maximum of one star for each
numbered item within the selection and exposure categories. A maximum of two stars could be allocated for comparability
Fig. 2 Meta-analysis of obstructive sleep apnea syndrome and the risk of metabolic syndrome for cross-sectional studies. AHI: apnea–hypopnea
index; OR: odds ratio; CI: confidence interval
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The Galbraith plot showed that the conference reports
greatly contributed to between-group heterogeneity
(Additional file 2: Figure S1, Additional file 3: Figure S2,
and Additional file 4: Figure S3)
Discussion
Our meta-analysis, which included 15 cross-sectional
(2456 patients with OSA and 1705 subjects with no
OSA) and five case–control studies (1156 OSA patients
and 404 controls), identified a significant relationship
between OSA and MS. This meta-analysis also showed
that the pooled ORs of MS in individuals with OSA
for the cross-sectional and case–control studies were
2.87 (95 % CI: 2.41–3.42) and 2.56 (95 % CI: 1.98–3.31),
respectively. Although there were substantial differ-
ences among studies (e.g., the diagnosis of OSA and
definition of MS), subgroup analyses confirmed the
robust relationship.
Fig. 4 Pooled crude odds ratios of metabolic syndrome in patients with mild or moderate-to-severe obstructive sleep apnea. OSA: obstructive
sleep apnea; OR: odds ratio; CI: confidence interval
Fig. 3 Meta-analysis of obstructive sleep apnea and the risk of metabolic syndrome for case–control studies. AHI: apnea–hypopnea index; OR:
odds ratio; CI: confidence interval
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Obesity is strongly linked to MS and is also a well-
known risk factor for OSA [48]. With the escalating
prevalence of obesity, the association between OSA and
MS has been increasingly recognized over the past few
years [16]. Several possible mechanisms have been sug-
gested to explain the biological plausibility of OSA, inde-
pendent of obesity, increasing the risk of MS [16]. These
mechanisms may be related to intermittent hypoxia
(IH), oxidative stress, cytokines, and selective activation
of systematic inflammation [49, 50]. Recurrent obstruct-
ive events result in IH in OSA. Repaid reoxygenation of
transiently ischemic tissues can damage tissues and
release reactive oxygen, the culprit of oxidative stress
[51]. IH and resultant oxidative stress have been pro-
posed as a pathogenetic pathway between OSA and
disturbance of glucose homeostasis [51], insulin resistance
[52], hypercholesterolemia [53], and hyperlipidemia [54].
Similarly, inflammatory cytokines (e.g., tumor necrosis
factor-α and interleukin-6) that are triggered by IH and
sleep fragmentation have been postulated as a putative
mechanism of MS. Inflammatory cytokines may also im-
pair insulin action in peripheral tissues and increase insu-
lin resistance, dyslipidemia, and hypertension in OSA [55].
In conclusion, OSA is linked with metabolic dysregulation
in the complex human biological system. IH and sleep
fragmentation are suggested to trigger an array of down-
stream effects (i.e., sympathetic activation, neurohumeral
changes, inflammation, and oxidative stress), which are
pathophysiological cascades that are common to the
pathogenesis of cardiometabolic diseases [16]. However, a
specific weakness of our study must be mentioned with
respect to pathophysiological aspects, which were not the
main focus of the review.
The shared relationship of OSA and MS with obesity
should be addressed. Obesity is a major risk factor for
OSA because it directly or indirectly contributes to
upper airway narrowing during sleep. An example of this
situation is by promoting enlargement of soft tissue
structures within and surrounding the airway, increasing
abdominal fat mass, and recumbent posture [56]. Add-
itionally, obesity, in particular abdominal obesity, is
thought to be connected with MS [12]. Our previous
study reported that the prevalence of MS in participants
with obesity was significantly higher than that in the
general population [57]. Therefore, obesity may play a
major potential confounding role and should be adjusted
in the relationship between OSA and MS. Our meta-
analysis showed that obesity, as well as age and sex,
could be adjusted as confounding factors in only 12 of
20 included studies. However, we found that all of the
studies evaluated obesity only by measuring and calcu-
lating BMI, and other accurate imaging examinations
(e.g., computed tomography, magnetic resonance im-
aging) were not performed. We also found that only four
studies further adjusted for smoking and alcohol drink-
ing [17, 33–35]. More importantly, none of the studies
adjusted for other important risk factors of MS (e.g.,
educational level, family or personal income, and family
history of diabetes or hypertension) [58], which would
be expected to reduce the positive association between
OSA and MS towards the null value.
We observed a substantial difference among the in-
cluded studies. An example of this difference was that
the normal limit of AHI for diagnosing OSA varied
Fig. 5 Funnel plots for assessment of publication bias among all
included studies in the meta-analysis
Table 3 Subgroup analyses
Excluded studies N Reasons Subgroup analysis
OR I2 (%) P value
Model 1 Parish, Angelico, Guill, Papanas, Agrawal,
Breuer, Ozol, Theorell-Haglöw, Assoumou,
Lin, Barreiro, Basoglu, Barcelo
13 Obesity as the most important factor unadjusted a: 2.74 20 0.29
b: 2.60 67 0.05
Model 2 Sasanabe 1 IDF criteria used a: 2.87 20 0.23
b: 3.11 23 0.27
Model 3 Redline, Guill, Gasa, Lin 4 Special population (children, young male, morbidly
obese individuals, and non-obese people)
a: 2.74 11 0.34
b: 2.63 19 0.19
a: cross-sectional studies; b: case–control studies
OR odd ratio, IDF International Diabetes Federation
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between studies. Most studies used a threshold of over
five events/h, and some used 10 events/h [28, 34, 41] or
15 events/h [17, 32, 36]. Furthermore, because MS is a
new concept with debatable criteria over a decade [11],
two definitions with individual waist circumference cri-
teria to define abdominal obesity in different ethnics
were adopted in our meta-analysis. Additionally, ad-
justed ORs were preferred in the meta-analysis. How-
ever, because of the fact that the relationship between
OSA and MS was not the primary outcome in some
studies, the adjusted ORs were not provided. Therefore,
we could only use raw data to calculate the crude ORs
in some included studies. In addition, although Papanas
et al. [18] suggested that a strong association became
non-significant when confounders were considered, the
adjusted ORs were not provided and the crude ORs,
which exhibited a significant difference, were thus
adopted. However, the results of the subgroup analyses
confirmed the robustness of association between OSA
and MS.
Our study has several potential limitations. First, the
included studies were cross-sectional or case–control
studies, and none were cohort studies, which could not
prove a cause-effect relationship between OSA and MS.
However, a beneficial effect of continuous positive air-
way pressure (CPAP) therapy on MS in patients with
OSA could provide more information about the causal
relationship [59]. Future randomized controlled trials are
required to investigate causality. Second, although the
adjusted ORs from each included study were preferred
in the meta-analysis, we could not exclude the possibility
that our results may have been influenced because ad-
justment for potential confounders differed in each
study. Third, selective outcome reporting remains a pos-
sibility. Some studies were speculated to be related to
the topic of OSA and MS, but adjusted ORs or raw data
were not obtained, despite attempting to contact authors
for additional published or unpublished data. Fourth, the
two methods that we adopted for assessing the severity
of OSA might not be appropriate because they were not
formally tested. This could be the possible reason for the
large heterogeneity in the meta-analysis of severity of
OSA on the risk of MS. Finally, the search was limited
to English-language studies only, which had the potential
of not including studies in other languages.
Conclusions
In summary, this meta-analysis of cross-sectional and
case–control studies confirms a positive association be-
tween OSA and MS, although causality between these
two factors has not been demonstrated yet. OSA and
the MS are important cardiovascular risk factors and
they may act synergistically. With the rapidly growing
health problem of OSA and MS, further population- or
community-based cohort and randomized controlled
studies with adequate adjustment for multiple major
confounding factors are required.
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